Journal of Urban Health

, Volume 82, Issue 3, pp 434–445 | Cite as

HIV among injection drug users in large US metropolitan areas, 1998

  • Samuel R. Friedman
  • Spencer Lieb
  • Barbara Tempalski
  • Hannah Cooper
  • Marie Keem
  • Risa Friedman
  • Peter L. Flom
Article

Abstract

This article estimates HIV prevalence rates among injection drug users (IDUs) in 95 large US metropolitan areas to facilitate social and policy analyses of HIV epidemics. HIV prevalence rates among IDUs in these metropolitan areas were calculated by taking the mean of two estimates: (1) estimates based on regression adjustments to Centers for Disease Control and Prevention (CDC) Voluntary HIV Counseling and Testing data and (2) estimates based on the ratio of the number of injectors living with HIV to the number of injectors living in the metropolitan area. The validity of the resulting estimates was assessed. HIV prevalence rates varied from 2 to 28% (median 5.9%; interquartile range 4.0–10.2%). These HIV prevalence rates correlated with similar estimates calculated for 1992 and with two theoretically related phenomena: laws against over-the-counter purchase of syringes and income inequality. Despite limitations in the accuracy of these estimates, they can be used for structural analyses of the correlates, predictors and consequences of HIV prevalence rates among drug injectors in metropolitan areas and for assessing and targeting the service needs for drug injectors.

Keywords

Epidemic modeling HIV prevalence estimates Injection drug users Local epidemics Structural analysis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996;86:642–654.PubMedGoogle Scholar
  2. 2.
    Hurley SF, Jolley DJ, Kaldor JM. Effectiveness of needle-exchange programs for prevention of HIV infection. Lancet. 1997;21:1797–1800.CrossRefGoogle Scholar
  3. 3.
    MacDonald M, Law M, Kaldor J, Hales J, Dore G. Effectiveness of needle and syringe programmes for preventing HIV transmission. Int J Drug Policy. 2000;14:351–352.Google Scholar
  4. 4.
    Friedman SR, Perlis TE, Lynch J, Des Jarlais DC. Economic inequality, poverty, and laws against syringe access as predictors of metropolitan area rates of drug injection and HIV infection. In: NIDA, eds. 2000 Global Research Network Meeting on HIV Prevention in Drug-Using Populations. Third Annual Meeting Report. Durban, South Africa, July 5–7, 2000. Washington, DC: US Department of Health and Human Services; 2001:147–149.Google Scholar
  5. 5.
    Office of Management and Budget. Standards for defining metropolitan and micropolitan statistical areas. Federal Register. 2000;65:8228–82238.Google Scholar
  6. 6.
    U.S. Bureau of the Census. State and Metropolitan Area Data Book, 1997–1998. Washington, DC: U.S. Bureau of the Census; 1998.Google Scholar
  7. 7.
    Lieb S, Friedman SR, Zeni MB, et al. An HIV prevalence-based model for estimating urban risk-populations of injection drug users and men who have sex with men. J Urban Health. 2004;81:401–415.PubMedGoogle Scholar
  8. 8.
    Friedman SR, Tempalski B, Cooper H, et al. Estimating numbers of IDUs in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for IDUs. J Urban Health. 2004;1:377–400.Google Scholar
  9. 9.
    Centers for Disease Control and Prevention. Adult HIV/AIDS Confidential Case Report Form CDC 50. 42A, Rev. 01/.2003;1:2003.Google Scholar
  10. 10.
    Centers for Disease Control and Prevention. Characteristics of persons living with AIDS and HIV, 2001. HIV/AIDS Surveillance Supplemental Report [serial online] 2003;9:2. Available at: http://www.cdc.gov/hiv/stats/hasrsuppVol9No2.htm. Accessed July 12, 2003.Google Scholar
  11. 11.
    Fleming PL, Byers RH, Sweeney PA, Daniels D, Karon JM, Janssen RS. HIV prevalence in the United States, 2000. Paper presented at 9th Conference on Retroviruses and Oppor-tunistic Infections; February 24–28, 2002; Seattle, Wash.Google Scholar
  12. 12.
    Perlis T, Des Jarlais DC. Laws prohibiting over-the-counter syringe sales to injection drug users: relations to population density, HIV prevalence, and HIV incidence. Am J Public Health. 2001;91:791–793.PubMedGoogle Scholar
  13. 13.
    Friedman SR, Tempalski B, Cooper H, Keem M, Friedman R, Flom PL. Structural factors to guide structural intervention: predictors of IDU population size, HIV prevalence among IDUs, and prevention program coverage for IDUs. Paper presented at: International Conference on AIDS; July 11–16, 2004; Bangkok, Thailand.Google Scholar
  14. 14.
    Des Jarlais DC, Perlis TE, Friedman SR, et al. Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991–96. Am J Public Health. 1998;88:1801–1806.PubMedGoogle Scholar
  15. 15.
    Des Jarlais DC, Marmor M, Friedmann P, et al. HIV incidence among injection drug users in New York City, 1992–97: evidence for a declining epidemic. Am J Public Health. 2000;90:352–359.PubMedCrossRefGoogle Scholar
  16. 16.
    Samuel MC, Doherty PM, Bulterys M, Jension SA. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiol Infect. 2001;127:475–484.PubMedCrossRefGoogle Scholar
  17. 17.
    Rothenberg R, Baldwin J, Trotter R, Muth S. The risk environment for HIV transmission: results from the Atlanta and Flagstaff network studies. J Urban Health. 2001;78:419–431.PubMedGoogle Scholar
  18. 18.
    Centers for Disease Control and Prevention. National HIV Prevalence Surveys 1997 Summary. Atlanta, GA. Centers for Disease Control and Prevention; 1998.Google Scholar
  19. 19.
    Monterroso ER, Hamburger ME, Vlahov D, et al. Prevention of HIV infection in street-recruited injection drug users. The Collaborative Injection Drug User Study (CIDUS). J Acquir Immune Defic Syndr. 2000;25:63–70.CrossRefPubMedGoogle Scholar
  20. 20.
    Shah NG, Celentano DD, Vlahov D, et al. Correlates of enrollment in methadone maintenance treatment programs differ by HIV-serostatus. AIDS. 2000;14:2035–2043.CrossRefPubMedGoogle Scholar
  21. 21.
    Strathdee SA, Safaeian M, Doherty M, Garfein RS, et al. Correlates of HIV infection among young new initiates to injection drug use in Baltimore, MD. 1994–2000. Paper presented at: XIV. International AIDS Conference; July 7–12, 2002; Barcelona, Spain.Google Scholar
  22. 22.
    Valente TW, Foreman RK, Junge B, Vlahov D. Needle-Exchange participation, effectiveness and policy: syringe relay, gender, and the paradox of public health. J Urban Health. 2001;78:340–349.PubMedGoogle Scholar
  23. 23.
    Ouellet LJ, Thorpe LE, Huo D, et al. Prevalence and incidence of HIV among out-of-treatment injecting drug users, Chicago 1994–96. J Acquir Immune Defic Syndr Hum Retrovirol. 2000;25:443–450.Google Scholar
  24. 24.
    Kwiatkowski CF, Corsi KF, Booth RE. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Soc Study Addict Alcohol Other Drugs. 2002;97:1–6.Google Scholar
  25. 25.
    California Department of Health Services. Consensus Meeting on HIV/AIDS Incidence and Prevalence in California: December, 2001; Sacramento, Calif.Google Scholar
  26. 26.
    Michigan Department of Public Health. 2002 Profile of HIV/AIDS in Region 5; 2003; Michigan Department of Public Health. Lansing, Mich.Google Scholar
  27. 27.
    Buchanan RJ, Smith SR. Drug-assistance programs funded by Title II of the Ryan White CARE Act: a survey of the states. AIDS Public Policy J. 1996;11:185–203.PubMedGoogle Scholar
  28. 28.
    Weeks MR, Clair S, Singer M, et al. High risk drug use sites, meaning and practice: implications for AIDS prevention. J Drug Issues. 2001;31:781–808.Google Scholar
  29. 29.
    Lopez-Zetina J, Kerndt P, Ford W, Woerhle T, Weber M. Prevalence of HIV and hepatitis B and self-reported injection risk behavior during detention among street-recruited injection drug users in Los Angeles County, 1994–96. Addiction. 2001; 96:589–595.CrossRefPubMedGoogle Scholar
  30. 30.
    Lopez-Zetina J, Norton D, Friis R, Rios-Ellis B, Kerndt P. Gender differences in participation in drug treatment among street-recruited injection drug users (IDUs) in Los Angeles County. Paper presented at XIV International AIDS Conference; July 7–12, 2002; Barcelona, Spain.Google Scholar
  31. 31.
    Murrill CS, Prevots DR, Miller MS, Linley LA, Royalty JE, Gwinn M. Incidence of HIV among injection drug users entering drug treatment programs in four US cities. J Urban Health. 2001;78:152–161.PubMedGoogle Scholar
  32. 32.
    Chitwood DD, Sanchez J, Comerford M, Page JB, McBride DC, Kitner KR. First injection and current risk factors for HIV among new and long-term injection drug users. AIDS Care. 2000;12:313–320.CrossRefPubMedGoogle Scholar
  33. 33.
    Longshore D, Annon J, Anglin MD. HIV prevalence among injection drug users in three northern California communities. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:200.PubMedGoogle Scholar
  34. 34.
    Clarke JG, Stein MD, Hanna L, Sobota M, Rich JD. Active and former injection drug users report of HIV risk behaviors during periods of incarceration. Subst Abuse. 2001;22:209–216.CrossRefGoogle Scholar
  35. 35.
    Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend. 2001;1:211–215.CrossRefGoogle Scholar
  36. 36.
    Zule WA, Desmond DP, Neff JA. Syringe type and drug injector risk for HIV infection: a case study in Texas. Soc Sci Med. 2002;55:1103–1113.CrossRefPubMedGoogle Scholar
  37. 37.
    Buchsbaum L, Stafford K, Velasco A. Risk Behavior Study: Injection Drug Users in San Diego County. San Diego, CA: County of San Diego Health and Human Services Agency, Office of AIDS Coordination; 1998.Google Scholar
  38. 38.
    McFarland W, Kellogg TA, Louie B, Murrill C, Katz MH. Low estimates of HIV seroconversions among clients of a drug treatment clinic in San Francisco, 1995–98. J Acquir Immune Defic Syndr. 2000;23:426–429.PubMedGoogle Scholar
  39. 39.
    Urban Health Study, AIDS Research Institute, University of California San Francisco, Urban Health Study Research Findings. Available at: http://www.ucsf.edu/uhs/program. html. Accessed February 4, 2005.Google Scholar
  40. 40.
    Gibson DR, Brand R, Anderson K, Kahn JG, Perales D, Guydish J. Two-to sixfold decreased odds of HIV risk behavior associated with use of syringe exchange. J Acquir Immune Defic Syndr. 2002;31:237–242.PubMedGoogle Scholar
  41. 41.
    Thiede H, Romero M, Bordelon K, Hagan H, Murrill CS. Using a jail-based survey to monitor HIV and risk behaviors among Seattle area injection drug users. J Urban Health. 2001;78:264–278.PubMedGoogle Scholar

Copyright information

© Oxford University Press on behalf of the New York Academy of Medicine 2005

Authors and Affiliations

  • Samuel R. Friedman
    • 1
    • 2
  • Spencer Lieb
    • 3
  • Barbara Tempalski
    • 4
  • Hannah Cooper
    • 5
    • 6
  • Marie Keem
    • 4
  • Risa Friedman
    • 4
  • Peter L. Flom
    • 7
  1. 1.Institute for AIDS ResearchNational Development and Research InstitutesNew York
  2. 2.Department of Epidemiology, Bloomberg School of Public HealthJohns Hopkins UniversityBaltimore
  3. 3.Bureau of HIV/AIDSFlorida Department of HealthTallahassee
  4. 4.National Development and Research Institutes, Inc.New York
  5. 5.Medical and Health Research Association of New York/National Development and Research Institutes, Inc.New York
  6. 6.Columbia Mailman School of Public HealthNew York
  7. 7.Statistics and Data Analysis CoreNational Development and Research Institutes, Inc.New York

Personalised recommendations